Webinar Series: Biologics to Biosimilars - How to Navigate These Novel Therapies

Elizabeth Moss, PharmD, BCACP, CDCES, delivers an illuminating webinar that dives deep into the intricate realm of biologics and biosimilars, offering valuable insights into their rigorous journey through the FDA's approval process. In this comprehensive presentation, she explores a range of pivotal aspects, including an introductory overview of biosimilars, emphasizing the distinctions between biosimilars and their biologic counterparts, and evaluating how these biosimilars measure up against the original biologics. Attendees gain an understanding of the practical implications of biosimilars in real-world healthcare settings and the crucial role of patient education in navigating these pioneering advancements. You will also learn about the current offerings in the market and those in the developmental pipeline.

 At the conclusion of this webinar participants will:

• Understand biologic medications and the FDA approval process.
• Define biosimilars and their role in specialty medication therapy management.
• Compare and contrast the pharmacologic options available for autoimmune disorders such as tumor necrosis factors inhibitors.
• Discuss tools to assist patients in understanding medication changes and review important counseling points.

CME Credits

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1AAPA Category 1 CME credits. Approval is valid from 10/12/2023 to 10/12/2024. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-2010144.